Sapropterin dihydrochloride is a synthetic analog of tetrahydrobiopterin (BH4) [1]. Its production does not directly rely on the sustainability of raw materials in the way that natural product extraction might [2]. Instead, sapropterin is manufactured through chemical synthesis [2]. The process involves a series of chemical reactions to create the desired molecule [2].
What is Sapropterin Used For?
Sapropterin dihydrochloride is a medication used to treat phenylketonuria (PKU) in patients with tetrahydrobiopterin-responsive PKU [3][4]. PKU is a rare genetic disorder where the body cannot properly break down the amino acid phenylalanine [3]. Sapropterin works by increasing the levels of BH4, a cofactor that helps the enzyme phenylalanine hydroxylase convert phenylalanine into tyrosine [3][4].
How is Sapropterin Made?
The production of sapropterin dihydrochloride involves a multi-step chemical synthesis [2]. This process begins with precursor molecules and uses various chemical reagents and conditions to build the sapropterin molecule [2]. The final product is then purified and formulated into its dosage form, typically as a powder for oral solution [1][2].
Are There Alternatives to Sapropterin for PKU?
The primary treatment for PKU is a strict low-phenylalanine diet [3]. For patients with BH4-responsive PKU, sapropterin is an adjunctive therapy to diet management [3][4]. Another medication, pegvaliase, is approved for PKU patients aged 16 and older who have inadequately controlled blood phenylalanine levels on a PKU diet alone [5]. Pegvaliase works by breaking down phenylalanine into smaller, less harmful molecules [5].
What are the Side Effects of Sapropterin?
Common side effects of sapropterin include headache, nasopharyngitis (common cold symptoms), nausea, vomiting, diarrhea, and abdominal pain [4]. Less common but serious side effects can include hypersensitivity reactions and hyperphenylalaninemia (high phenylalanine levels) [4].
What is Phenylketonuria (PKU)?
Phenylketonuria (PKU) is an inherited metabolic disorder that affects about 1 in 10,000 to 1 in 17,000 newborns in the United States [3]. It is caused by mutations in the PAH gene, which provides instructions for making the enzyme phenylalanine hydroxylase [3]. This enzyme is essential for metabolizing phenylalanine [3]. Without adequate phenylalanine hydroxylase activity, phenylalanine builds up in the blood and body tissues, which can lead to intellectual disability and other health problems if left untreated [3].
How is BH4 Deficiency Diagnosed?
Tetrahydrobiopterin (BH4) deficiency is diagnosed through biochemical and genetic testing [6]. Biochemical tests can measure levels of biopterin and neopterin in blood and urine, as well as phenylalanine and tyrosine levels [6]. Genetic testing can identify mutations in genes associated with BH4 metabolism, such as GCH1, PTS, QDPR, and DHFR [6].
How Does Sapropterin Help Patients with PKU?
Sapropterin helps patients with BH4-responsive PKU by increasing the activity of the deficient or defective phenylalanine hydroxylase enzyme [3][4]. By acting as a synthetic cofactor for this enzyme, sapropterin enables the body to more effectively break down phenylalanine, thereby reducing its levels in the blood [3][4]. This can help prevent or mitigate the neurological damage associated with high phenylalanine concentrations [3].
What is the Typical Dosage of Sapropterin?
The typical starting dose of sapropterin dihydrochloride for treating PKU is 10 mg/kg once daily, administered orally [4]. The dose may be adjusted based on the patient's individual response and blood phenylalanine levels, up to a maximum of 20 mg/kg once daily [4]. Patients should continue to adhere to their prescribed low-phenylalanine diet while taking sapropterin [4].
What are the Regulatory Approvals for Sapropterin?
Sapropterin dihydrochloride is approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of BH4-responsive PKU in adult and pediatric patients [3][7]. It is marketed under brand names like Kuvan [3].
Sources:
[1] https://www.rxlist.com/kuvan-drug.htm
[2] https://www.ncbi.nlm.nih.gov/books/NBK542299/
[3] https://rarediseases.info.nih.gov/diseases/6533/phenylketonuria
[4] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/kuvan-sapropterin-dihydrochloride-information
[5] https://www.fda.gov/vaccines-blood-biologics/approved-biologics/palynziq-pegvaliase-o-gpx-injection
[6] https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=799
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/kuvan